Skip to content

Convergence Insufficiency Treatment Trial (CITT)

Convergence Insufficiency Treatment Trial (CITT)

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00338611
Enrollment
221
Registered
2006-06-20
Start date
2005-07-31
Completion date
2009-09-30
Last updated
2010-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Binocular Vision Disorder, Convergence Insufficiency

Keywords

vision therapy, orthoptics, pencil push-up therapy

Brief summary

The purposes of the CITT are: * To determine whether Home-based Pencil Push-up therapy, Home-based Pencil Push-ups with Computer Vision Therapy/Orthoptics or Office-based VT/Orthoptics more effective than placebo treatment, and whether there are differences between the three treatments in improving subject symptoms and signs. * To evaluate whether improvements in outcome measures are still present after one year of observation.

Detailed description

Convergence insufficiency is a prevalent and distinct binocular vision disorder. Typical symptoms include double vision, eyestrain, headaches, and blurred vision while reading. It affects approximately 5% of children in the United States, and may have a serious impact on an individual's performance in school, choice of jobs, and quality of life. There is no consensus regarding the most effective treatment for convergence insufficiency. Two commonly prescribed treatments are home-based pencil push-up therapy and office-based vision therapy/orthoptics. Significant differences exist between these two treatment modalities in cost and number of office visits required, with pencil push-up therapy being less expensive and less time intensive. There have been no well-designed studies that have compared the effectiveness of these two treatments. The Convergence Insufficiency Treatment Trial (CITT) is a prospective, masked, placebo-controlled, multi-center clinical trial in which 208 subjects between the ages of 9 to \< 18 years will be randomly assigned to: 1) Home-based Pencil Push-Up Therapy, 2) Home-based Pencil Push-ups with Computer Vision Therapy/Orthoptics, 3) Office-based Vision Therapy/Orthoptics, or 4) Placebo Office-based Vision Therapy/Orthoptics. The primary outcome measure is a measure of symptoms using a 15-item survey, the CI Symptom Survey. Secondary outcome measures are two common clinical tests of the eyes' ability to converge when performing close work. Patients will be tested at the eligibility examination, and by masked examiners after 4, 8 and 12 weeks of treatment have been completed during the 12-week treatment phase. Long term follow-up will be assessed at 6 and 12 months after the completion of active treatment.

Interventions

BEHAVIORALHome-based Pencil Push-Up Therapy

Exercise in which patients visually followed a small letter on a pencil as they moved the pencil closer to the bridge of their nose

BEHAVIORALHome-based Pencil Push-ups with Computer Vision Therapy/Orthoptics

Exercise in which patients visually followed a small letter on a pencil as they moved the pencil closer to the bridge of their nose combined with additional computer vision therapy

BEHAVIORALOffice-based Vision Therapy/Orthoptics

Weekly hour-long sessions of office-based vision therapy with a trained therapist and performed at-home reinforcement exercises

BEHAVIORALPlacebo Office-based Vision Therapy/Orthoptics

Vision activities designed to simulate office-based therapy

Sponsors

National Eye Institute (NEI)
Lead SponsorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
9 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Children between the ages of 9 and 17 years with symptomatic convergence insufficiency * Exophoria at near at least 4Δ greater than at far * Insufficient positive fusional convergence at near * A receded near point of convergence of ≥6 cm break * CI Symptom Survey score ≥16

Exclusion criteria

* Previous treatment with office-based vision therapy/orthoptics or pencil push-ups * Systemic diseases known to affect accommodation, vergence and ocular motility * Developmental disability, mental retardation, attention deficit hyperactivity disorder (ADHD), or learning disability diagnosis that in the investigator's discretion would interfere with treatment

Design outcomes

Primary

MeasureTime frame
Measure of symptoms using a 15-item Convergence Insufficiency Symptom Survey12 weeks

Secondary

MeasureTime frame
Eyes' ability to converge when performing close work12 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 4, 2026